GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...

The U.S Food and Drug Administration has approved Nucala, British drugmaker GSK's asthma drug, to treat some patients with a ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and ...

GSK has gained approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab), as ...

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...

GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence.

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth ...

(Alliance News) - GSK PLC on Thursday said the US Food & Drug Administration has approved its asthma drug Nucala as an add-on maintenance treatment for adults with chronic obstructive pulmonary ...

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for Nucala (mepolizumab) as an add-on ...

GSK’s (LSE: GSK) biologic therapy Nucala (mepolizumab) has demonstrated a consistent reduction in exacerbation rates among ...